Ivermectin, Fenbendazole, and Mebendazole in Stage IV Prostate Cancer: Case Series Review and Subgroup Analysis from 37 Publicly Reported Anecdotal Cases (2024–2026)
.png)
Abstract Background: Repurposed antiparasitic agents—ivermectin (IVM), fenbendazole (FBZ), and mebendazole (MBZ)—have generated public interest as potential adjunctive therapies in advanced malignancies, including stage IV prostate cancer. This narrative review analyzes 37 publicly reported anecdotal cases compiled in a 2025 Substack article (updated 2026) primarily sourced from Dr. William Makis’ X posts. Methods: Cases were extracted from the source article, which organizes 22 core cases into drug-focused tables and lists 15 additional testimonials. Data abstraction focused on patient demographics, disease characteristics, treatment regimens, prior therapies, adjuncts, PSA kinetics, imaging outcomes, and clinical responses. Subgroup analysis was performed by primary regimen, background therapy, adjunct use, and response depth. Results: All patients were adult males (ages 53–80) with Gleason 7–9 stage IV prostate cancer, predominantly bone-metastatic. The dominant regimen was IVM (...